Publication
Article
Supplements and Featured Publications
Take CME Quiz Online
CME/CE QUESTIONS
Accreditation Statement
Physicians Continuing Medical Education
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through sponsorship of Professional Resources In Management Education, Inc (PRIME®). PRIME® is accredited by ACCME to provide continuing medical education for physicians. PRIME® designates this educational activity for a maximum of 2.0 category 1 credits toward the AMA Physician's Recognition Award. Physicians should claim only those hours of credit that they actually spent on this activity.
Pharmacists Continuing Education
PRIME® is approved by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education and complies with the Criteria for Quality for continuing pharmacyl education programming. The universal program number for this activity is 255-000-05-025-H01. This activity is approved for 2.0 contact hours by PRIME®. In order to receive a Statement of Credit for this activity, pharmacists must read the program, successfully pass the posttest, and complete the program evaluation.
Nursing Continuing Education
PRIME® designates this educational activity for 2.0 contact hours by the Florida Board of Nursing and the California Board of Registered Nursing.
Case Management Continuing Education
The Commission for Case Manager Certification has approved this educational activity for 2.0 contact hours for certified case managers through PRIME®.
1. Because of the significant investment of resources within managed care, including asthma disease management models, case management, population health initiatives, and recently imposed pharmacy-based adherence protocols, the costs associated with asthma have substantially decreased.
2. Asthma is a chronic inflammatory disorder of the airways that is characterized by recurrent episodes of all of the following except:
3. The gold standard in diagnosing asthma is spirometry.
4. Managing asthma involves the following components:
5. Reasons responsible for lack of adherence to clinical guidelines include all but which of the following?
6. Most patients tend to be accurate when reporting to their primary physicians on the severity of their condition but underestimate their level of control regarding the disease.
7. Patients with moderate-to-severe persistent asthma who continue to have exacerbations may benefit from treatment with which of the following?
8. Anxiety and depression have no impact on the management of patients with mild-to-moderate severe asthma.
9. Managed care companies are uniquely poised to assist the provider in managing the asthma patient.
10. Utilization of guidelines and evolving concepts of asthma control versus asthma severity can be important in improving the management of patients with asthma.
Program Evaluation for Discussing the COSTS of Asthma: Controlling Outcomes, Symptoms, and Treatment Strategies
To receive CME/CE instantly please:
There is no cost to participate in this activity, as it is supported through an educational grant from Genentech, Inc and Novartis Pharmaceuticals, Inc.
Original Release Date: November 1, 2005
Expiration Date: October 31, 2006
Program Evaluation
PRIME® values your opinion and asks you to assist us in evaluating the effectiveness of this activity and to make recommendations for future educational offerings. Please complete this evaluation form by circling the most appropriate rating using the following scale.
1 = Poor, 2 = Fair, 3 = Satisfactory, 4 = Good, 5 = Excellent
The goal of this program is to provide information that professionals can use in their daily practice to improve the quality of life for the asthma patient by understanding how to decrease symptoms, decrease morbidity, and decrease the use of healthcare resources.
Rate the extent to which the program met the identified objectives:
Define guideline-based asthma control and its applicability to the management of asthma in the managed care setting.
1 2 3 4 ; 5
State the effects of current asthma treatment options on lung function, resource utilization, and symptom control, as well as the proper position of these agents in asthma treatment regimens.
1 2 3 4 ; 5
Describe reasons for suboptimal patient outcomes and discuss methods to improve such outcomes in managed care-based comprehensive asthma management programs.
1 2 3 4 ; 5
Relevance to Practice: Please choose the most appropriate answer:
Application to Practice: Please choose the most appropriate answer:
The information was presented in a fair and balanced manner. Yes ___ No___
If no, please explain:
______________________________________________________________________________________________________________________________________________________________
Recommendations for further information on this topic or other areas of interest in your professional practice:
______________________________________________________________________________________________________________________________________________________________
Intended Audience
Medical directors, pharmacists, case managers, and nurses in managed care organizations.
Learning Objectives
Accreditation Statement
Physicians Continuing Medical Education
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through sponsorship of Professional Resources In Management Education, Inc (PRIME®). PRIME® is accredited by ACCME to provide continuing medical education for physicians. PRIME® designates this educational activity for a maximum of 2.0 category 1 credits toward the AMA Physician's Recognition Award. Physicians should claim only those hours of credit that they actually spent on this activity.
Pharmacists Continuing Education
PRIME® is approved by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education and complies with the Criteria for Quality for continuing pharmaceutical education programming. The universal program number for this activity is 255-000-05-025-H01. This activity is approved for 2.0 contact hours by PRIME®. In order to receive a Statement of Credit for this activity, pharmacists must read the program, successfully pass the posttest, and complete the program evaluation.
Nursing Continuing Education
PRIME® designates this educational activity for 2.0 contact hours by the Florida Board of Nursing and the California Board of Registered Nursing.
Case Management Continuing Education
The Commission for Case Manager Certification has approved this educational activity for 2.0 contact hours for certified case managers through PRIME®.
To Receive Your CME/CE Credit
Instant CME/CE:
There is no cost for this activity.
Acknowledgment of Commercial Support
This program is supported by an unrestricted educational grant from Genentech Inc. and Novartis Pharmaceuticals Inc.
Original Release Date: November 1, 2005
Expiration Date: October 31, 2006